Literature DB >> 33447234

Efficacy and Safety of Treatments to Improve Dyspareunia in Breast Cancer Survivors: A Systematic Review.

Nicolás Mendoza1, Rosalía Carrión1, Loreto Mendoza-Huertas1, Ana Rosa Jurado1,2.   

Abstract

OBJECTIVE: To analyse all available evidence to validate the effectiveness of a local intervention in the treatment of dyspareunia in breast cancer survivors (BCS).
METHODS: We searched the Institute of Scientific Information Web of Knowledge, MEDLINE, PubMed, Scopus, and Cochrane databases for all articles published in peer-reviewed journals up to April 2019. The PICOS standards were: (population) BCS with dyspareunia; (intervention) any type of vulvovaginal treatment; (main outcome) frequency and severity of dyspareunia; (study design) clinical studies.
RESULTS: The literature search strategy identified 252 articles, of which 233 were excluded at various stages of the search. Finally, we systematically reviewed 19 studies, 8 with local hormonal therapies, 7 with local non-hormonal therapies, 3 with laser therapy, and 1 with other interventions. Of the studies, 7 were randomized control trials and 11 were prospective observations. Most of the interventions were shown to be effective and safe in the improvement of dyspareunia.
CONCLUSION: In addition to the traditional options already analysed in other current reviews, other interesting options are highlighted (such as laser or local dehydroepiandrosterone [DHEA]). Further work on dyspareunia should make use of high-quality trials with large numbers of samples to obtain evidence that could adequately demonstrate key methodological characteristics and harmful effects.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Breast cancer; Breast cancer survivor; Dyspareunia; Female sexual dysfunction; Vaginal therapy

Year:  2020        PMID: 33447234      PMCID: PMC7768121          DOI: 10.1159/000506148

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  33 in total

1.  Sexual Problems of Patients With Breast Cancer After Treatment: A Systematic Review.

Authors:  Yun-Chen Chang; Shiow-Ru Chang; Shih-Che Chiu
Journal:  Cancer Nurs       Date:  2019 Sep/Oct       Impact factor: 2.592

2.  Incidence and severity of sexual dysfunction among women with breast cancer: a meta-analysis based on female sexual function index.

Authors:  Liwei Jing; Chao Zhang; Wei Li; Feng Jin; Aiping Wang
Journal:  Support Care Cancer       Date:  2019-02-02       Impact factor: 3.603

3.  Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors.

Authors:  Marco Gambacciani; Marco Levancini
Journal:  Menopause       Date:  2017-03       Impact factor: 2.953

4.  Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects.

Authors:  Angelamaria Becorpi; Giuseppina Campisciano; Nunzia Zanotta; Zelinda Tredici; Secondo Guaschino; Felice Petraglia; Annalisa Pieralli; Giovanni Sisti; Francesco De Seta; Manola Comar
Journal:  Lasers Med Sci       Date:  2018-03-01       Impact factor: 3.161

5.  Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors.

Authors:  Annalisa Pieralli; Maria Grazia Fallani; Angelamaria Becorpi; Claudia Bianchi; Serena Corioni; Manuela Longinotti; Zelinda Tredici; Secondo Guaschino
Journal:  Arch Gynecol Obstet       Date:  2016-05-12       Impact factor: 2.344

6.  Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.

Authors:  Sabrina Witherby; Julia Johnson; Laurence Demers; Sharon Mount; Benjamin Littenberg; Charles D Maclean; Marie Wood; Hyman Muss
Journal:  Oncologist       Date:  2011-03-08

7.  Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors.

Authors:  A Kendall; M Dowsett; E Folkerd; I Smith
Journal:  Ann Oncol       Date:  2006-01-27       Impact factor: 32.976

Review 8.  Sexual dysfunction in women with cancer: a systematic review with meta-analysis of studies using the Female Sexual Function Index.

Authors:  Maria Ida Maiorino; Paolo Chiodini; Giuseppe Bellastella; Dario Giugliano; Katherine Esposito
Journal:  Endocrine       Date:  2015-12-07       Impact factor: 3.633

9.  Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.

Authors:  Peter Kenemans; Nigel J Bundred; Jean-Michel Foidart; Ernst Kubista; Bo von Schoultz; Piero Sismondi; Rena Vassilopoulou-Sellin; Cheng Har Yip; Jan Egberts; Mirjam Mol-Arts; Roel Mulder; Steve van Os; Matthias W Beckmann
Journal:  Lancet Oncol       Date:  2009-01-23       Impact factor: 41.316

Review 10.  Management of sexual dysfunction in breast cancer survivors: a systematic review.

Authors:  Susan M Seav; Sally A Dominick; Boris Stepanyuk; Jessica R Gorman; Diana T Chingos; Jennifer L Ehren; Michael L Krychman; H Irene Su
Journal:  Womens Midlife Health       Date:  2015-11-02
View more
  1 in total

1.  Sexual Dysfunction in Postmenopausal Women with Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.

Authors:  Daniel María Lubián López; Carmen Aisha Butrón Hinojo; Manuel Sánchez-Prieto; Nicolás Mendoza; Rafael Sánchez-Borrego
Journal:  Breast Care (Basel)       Date:  2020-10-23       Impact factor: 2.268

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.